Volume XXV No. 5 – March 26, 2018
In this issue:
HERE’S A FIRST LOOK at an important new trend: At first, it probably will have the greatest impact on anatomic pathology groups that perform cancer tests. But even clinical labs will find themselves dealing with new factors in the lab testing marketplace—particularly the ability to access or license valuable assays that incorporate the latest diagnostic technologies. Also in this issue are the latest developments in the tale of a lab company that made an early splash in drugs-of-abuse and pain management testing almost two decades ago, but is now going out of business, in part due to lingering allegations of abusive sales and billing practices.